Skip to content

Study · Randomized controlled trial · n = 160 · 1996

11 results

A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation.

Garry R, Khair A, Mooney P, Stuart M

British journal of obstetrics and gynaecology1 Apr 1996Cited by 22 (Europe PMC)

PMID8605131 (opens in a new tab)DOI10.1111/j.1471-0528.1996.tb09739.x (opens in a new tab)PepBankPUB-08605131
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with dysfunctional uterine bleeding, goserelin and danazol were equally effective in thinning the endometrium.

    In plain wordsGoserelin and danazol were equally effective in thinning the endometrium.

    Peptide
    Goserelin
    Outcome
    No significant changeEndometrial thinning
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The two drugs were equally effective in thinning the endometrium.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  2. 02HumanRandomized controlled trialSafety outcome

    In premenopausal women, goserelin was better tolerated than danazol.

    In plain wordsGoserelin was better tolerated than danazol.

    Peptide
    Goserelin
    Outcome
    IncreaseTolerability
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with danazol, goserelin was better tolerated
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, goserelin produced a more satisfactory endometrial appearance at hysteroscopy than danazol.

    In plain wordsGoserelin produced a more satisfactory endometrial appearance than danazol.

    Peptide
    Goserelin
    Outcome
    IncreaseEndometrial appearance
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Compared with danazol, goserelin was better tolerated and resulted in a more satisfactory endometrial appearance at hysteroscopy
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, cavity length fell by 0.5 cm with goserelin versus 0.3 cm with danazol, P = 0.002.

    In plain wordsGoserelin reduced cavity length more than danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseCavity length reduction
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Reduction in cavity length
    0.5 cm
    goserelin
    Reduction in cavity length
    0.3 cm
    danazol

    Source sentences

    Summary
    a greater reduction in cavity length (0.5 cm compared with 0.3 cm, P = 0.002)
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, operation duration was 16.4 min with goserelin versus 21.6 min with danazol, P < 0.001.

    In plain wordsOperations were shorter with goserelin than danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseOperation duration
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Operation duration
    16.4 min
    goserelin
    Operation duration
    21.6 min
    danazol

    Source sentences

    Summary
    a shorter operation (16.4 min compared with 21.6 min, P < 0.001)
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, fluid absorption was 0 ml with goserelin versus 200 ml with danazol, P = 0.001.

    In plain wordsFluid absorption was lower with goserelin than danazol.

    Peptide
    Goserelin
    Outcome
    DecreaseFluid absorption
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Fluid absorbed during surgery
    0 ml
    goserelin
    Fluid absorbed during surgery
    200 ml
    danazol

    Source sentences

    Summary
    less fluid absorption (0 ml compared with 200 ml, P = 0.001)
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, amenorrhoea or oligoamenorrhoea occurred in 77% with goserelin versus 54% with danazol at six months, P < 0.001.

    In plain wordsGoserelin produced more amenorrhoea or oligoamenorrhoea than danazol.

    Peptide
    Goserelin
    Outcome
    IncreaseAmenorrhoea or oligoamenorrhoea
    Study

    n = 160

    Comparator
    Danazol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneousAs given in this study (human).

    Measurements

    Amenorrhoea or oligoamenorrhoea at the six month check
    77%
    goserelin
    Amenorrhoea or oligoamenorrhoea at the six month check
    54%
    danazol

    Source sentences

    Summary
    and a higher rate of amenorrhoea or oligoamenorrhoea (77% compared with 54%, P < 0.001) at the six month check.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, 8 weeks of goserelin produced greater endometrial thinning on ultrasound than 4 weeks.

    In plain wordsEight weeks of goserelin thinned the endometrium more than four weeks on ultrasound.

    Peptide
    Goserelin
    Outcome
    DecreaseUltrasound endometrial thinning
    Study

    n: not reported in source

    Comparator
    4 weeks of goserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The administration of goserelin for 8 weeks compared with 4 weeks produced greater thinning of the endometrium on ultrasound and on histological examination, a greater reduction in cavity length on ultrasound and an increase in reported vasomotor symptoms.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, 8 weeks of goserelin produced greater histological endometrial thinning than 4 weeks.

    In plain wordsEight weeks of goserelin produced greater histological thinning than four weeks.

    Peptide
    Goserelin
    Outcome
    DecreaseHistological endometrial thinning
    Study

    n: not reported in source

    Comparator
    4 weeks of goserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The administration of goserelin for 8 weeks compared with 4 weeks produced greater thinning of the endometrium on ultrasound and on histological examination, a greater reduction in cavity length on ultrasound and an increase in reported vasomotor symptoms.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In premenopausal women, 8 weeks of goserelin reduced cavity length more than 4 weeks on ultrasound.

    In plain wordsEight weeks of goserelin reduced cavity length more than four weeks.

    Peptide
    Goserelin
    Outcome
    DecreaseUltrasound cavity length
    Study

    n: not reported in source

    Comparator
    4 weeks of goserelin
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The administration of goserelin for 8 weeks compared with 4 weeks produced greater thinning of the endometrium on ultrasound and on histological examination, a greater reduction in cavity length on ultrasound and an increase in reported vasomotor symptoms.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.
  11. 11HumanRandomized controlled trialSafety outcome

    In premenopausal women, 8 weeks of goserelin increased reported vasomotor symptoms versus 4 weeks.

    In plain wordsEight weeks of goserelin caused more reported vasomotor symptoms than four weeks.

    Peptide
    Goserelin
    Outcome
    IncreaseVasomotor symptoms
    Study

    n: not reported in source

    Comparator
    4 weeks of goserelin
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    3.6 mg · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The administration of goserelin for 8 weeks compared with 4 weeks produced greater thinning of the endometrium on ultrasound and on histological examination, a greater reduction in cavity length on ultrasound and an increase in reported vasomotor symptoms.
    3 context sentences
    Summary · context
    A prospective open randomised trial.
    Summary · context
    One hundred and sixty premenopausal women with dysfunctional uterine bleeding.
    Summary · context
    Randomisation into four groups receiving either one or two injections of goserelin acetate (3.6 mg subcutaneously) or 28 or 56 days of danazol (four 200 mg tablets daily), followed by endometrial laser ablation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.